NO3044319T3 - - Google Patents
Info
- Publication number
- NO3044319T3 NO3044319T3 NO15731377A NO15731377A NO3044319T3 NO 3044319 T3 NO3044319 T3 NO 3044319T3 NO 15731377 A NO15731377 A NO 15731377A NO 15731377 A NO15731377 A NO 15731377A NO 3044319 T3 NO3044319 T3 NO 3044319T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1719—Muscle proteins, e.g. myosin or actin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14174848.3A EP2960336A1 (fr) | 2014-06-27 | 2014-06-27 | Traitement systémique efficace de pathologies dystrophiques musculaires |
| PCT/EP2015/058964 WO2015197232A1 (fr) | 2014-06-27 | 2015-04-24 | Traitement systémique efficace de pathologies musculaires dystrophiques |
| PCT/EP2015/064703 WO2015197869A1 (fr) | 2014-06-27 | 2015-06-29 | Traitement systémique efficace de pathologies dystrophiques |
| EP15731377.6A EP3044319B1 (fr) | 2014-06-27 | 2015-06-29 | Traitement systémique efficace de pathologies dystrophiques musculaires |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO3044319T3 true NO3044319T3 (fr) | 2018-11-03 |
Family
ID=51033008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO15731377A NO3044319T3 (fr) | 2014-06-27 | 2015-06-29 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10166272B2 (fr) |
| EP (3) | EP2960336A1 (fr) |
| JP (3) | JP6656240B2 (fr) |
| CN (2) | CN106659804A (fr) |
| CA (1) | CA2953187A1 (fr) |
| DK (1) | DK3044319T3 (fr) |
| ES (1) | ES2679621T3 (fr) |
| NO (1) | NO3044319T3 (fr) |
| TR (1) | TR201811260T4 (fr) |
| WO (2) | WO2015197232A1 (fr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2960336A1 (fr) * | 2014-06-27 | 2015-12-30 | Genethon | Traitement systémique efficace de pathologies dystrophiques musculaires |
| RU2716991C2 (ru) | 2014-11-05 | 2020-03-17 | Вояджер Терапьютикс, Инк. | Полинуклеотиды aadc для лечения болезни паркинсона |
| CN107250364A (zh) | 2015-01-16 | 2017-10-13 | 华盛顿大学 | 新的微小肌养蛋白及相关使用方法 |
| KR102877920B1 (ko) | 2015-11-16 | 2025-10-30 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | 티틴-기반 근증 및 다른 티틴성병증의 치료를 위한 물질 및 방법 |
| FI3442600T3 (fi) | 2016-04-15 | 2024-05-14 | Res Inst Nationwide Childrens Hospital | Adeno-assosioidulla virusvektorilla b-sarkoglykaanin ja mikro-rna-29:n toimittaminen ja lihasdystrofian hoito |
| MA45477A (fr) | 2016-04-15 | 2019-02-20 | Res Inst Nationwide Childrens Hospital | Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire |
| CA2971303A1 (fr) | 2016-06-21 | 2017-12-21 | Bamboo Therapeutics, Inc. | Genes de mini-dystrophine optimises et cassettes d'expression et leur utilisation |
| MX2019000962A (es) | 2016-07-26 | 2019-08-01 | Biomarin Pharm Inc | Novedosas proteinas de la capside del virus adenoasociado. |
| CN110997923B (zh) * | 2017-03-17 | 2024-01-02 | 全国儿童医院研究所 | 腺相关病毒载体递送肌肉特异性微肌营养不良蛋白以治疗肌营养不良症 |
| US11338045B2 (en) | 2017-03-17 | 2022-05-24 | Newcastle University | Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy |
| AU2018241847A1 (en) | 2017-03-27 | 2019-10-17 | Vrije Universiteit Brussel | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| US12084673B2 (en) * | 2017-10-17 | 2024-09-10 | Fundació Institut D'investigació En Ciencies De La Salut Germans Trias I Pujol | Vectors for the treatment of Friedreich's ataxia |
| EP3697915A4 (fr) | 2017-10-18 | 2021-12-08 | Research Institute at Nationwide Children's Hospital | Administration par vecteur à virus adéno-associé de micro-dystrophine spécifique de muscles pour traiter la dystrophie musculaire |
| GB201720224D0 (en) | 2017-12-05 | 2018-01-17 | Royal Holloway & Bedford New College | Treatment of muscular dystrophies |
| AU2019216257B2 (en) | 2018-01-31 | 2025-11-20 | Research Institute At Nationwide Children's Hospital | Gene therapy for limb-girdle muscular dystrophy type 2C |
| WO2019217513A2 (fr) | 2018-05-09 | 2019-11-14 | Biomarin Pharmaceutical Inc. | Méthodes de traitement de la grippe |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| BR112020023082A2 (pt) | 2018-05-15 | 2021-02-09 | Voyager Therapeutics, Inc. | composições e métodos para o tratamento de doença de parkinson |
| CN120393053A (zh) | 2018-06-18 | 2025-08-01 | 全国儿童医院研究所 | 用于治疗肌营养不良的肌肉特异性微小肌营养不良蛋白的腺相关病毒载体递送 |
| WO2020006458A1 (fr) | 2018-06-29 | 2020-01-02 | Research Institute At Nationwide Children's Hospital | Produits de virus adéno-associés recombinants et méthodes de traitement de la dystrophie des ceintures 2a |
| CA3114621A1 (fr) | 2018-09-28 | 2020-04-02 | Voyager Therapeutics, Inc. | Constructions d'expression de frataxine comprenant des promoteurs modifies et leurs methodes d'utilisation |
| US12377170B2 (en) | 2019-02-26 | 2025-08-05 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of β-sarcoglycan and the treatment of muscular dystrophy |
| IT201900002929A1 (it) | 2019-02-28 | 2020-08-28 | Turatti Srl | Procedimento per estrazione selettiva di principi attivi e/o oleoresine da materiale vegetale e relativo impianto |
| JP7635139B2 (ja) * | 2019-03-25 | 2025-02-25 | ジェネトン | オーバーラップａａｖベクターを使用する大きいサイズのクアシジストロフィンの産生 |
| JP2022534119A (ja) | 2019-05-30 | 2022-07-27 | ソリッド・バイオサイエンシーズ・インコーポレーテッド | 組換えヘルペスウイルスベクター |
| EP4017871B1 (fr) | 2019-08-21 | 2024-01-17 | Research Institute at Nationwide Children's Hospital | Administration de vecteur de virus adéno-associé d'alpha-sarcoglycane et traitement de dystrophie musculaire |
| EP4100021A4 (fr) * | 2020-02-03 | 2023-11-15 | Rutgers, the State University of New Jersey | Compositions de micro-arn-7 destinées à favoriser la récupération fonctionnelle à la suite d'un traumatisme médullaire et leurs procédés d'utilisation |
| BR112022021635A2 (pt) | 2020-04-29 | 2022-12-06 | Bristol Myers Squibb Co | Distrofinas miniaturizadas tendo domínios de fusão de espectrina e usos das mesmas |
| WO2021231863A1 (fr) * | 2020-05-14 | 2021-11-18 | The Trustees Of The University Of Pennsylvania | Compositions utiles dans le traitement de la maladie de pompe |
| WO2022029543A1 (fr) * | 2020-08-06 | 2022-02-10 | Intas Pharmaceuticals Ltd. | Administration par vecteur de virus adéno-associé de micro-dystrophine pour traiter la dystrophie musculaire |
| WO2022076750A2 (fr) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Virus adéno-associés recombinants pour administration musculaire ou dans le snc |
| WO2022122733A1 (fr) | 2020-12-08 | 2022-06-16 | Genethon | Nouvelle thérapie génique pour le traitement de la dystrophie musculaire de duchenne |
| WO2022216749A1 (fr) | 2021-04-05 | 2022-10-13 | Solid Biosciences Inc. | Vecteur du virus de l'herpès simplex recombinant |
| EP4119682A1 (fr) | 2021-07-13 | 2023-01-18 | Genethon | Procédé permettant de déterminer la nature d'impuretés d'adn à l'intérieur de particules virales |
| EP4413018A1 (fr) | 2021-10-07 | 2024-08-14 | RegenxBio Inc. | Virus adéno-associés recombinants pour administration ciblée |
| JP2023059858A (ja) | 2021-10-15 | 2023-04-27 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 自己相補的アデノ随伴ウイルスベクター及び筋ジストロフィーの治療におけるその使用 |
| EP4215614A1 (fr) | 2022-01-24 | 2023-07-26 | Dynacure | Thérapie de combinaison pour maladies liées à la dystrophine |
| EP4230196A1 (fr) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Composés à utiliser dans le traitement des dystrophinopathies |
| WO2024216244A2 (fr) | 2023-04-13 | 2024-10-17 | Regenxbio Inc. | Ciblage de capsides d'aav, méthodes de fabrication et d'utilisation de ceux-ci |
| WO2025017168A1 (fr) | 2023-07-19 | 2025-01-23 | Genethon | Nouveaux micro-gènes d'utrophine optimisés |
| WO2025017169A1 (fr) | 2023-07-20 | 2025-01-23 | Genethon | Nouvelles mididystrophines |
| WO2025096910A1 (fr) * | 2023-11-02 | 2025-05-08 | The Curators Of The University Of Missouri | Microdystrophine humaine à codon optimisé sans cpg pour la thérapie génique de la dystrophie musculaire de duchenne |
| WO2025250909A1 (fr) | 2024-05-31 | 2025-12-04 | Sarepta Therapeutics, Inc. | Vaa recombinant myotrope |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| EP1366160B1 (fr) | 2000-10-06 | 2008-07-09 | The Regents Of The University Of Michigan | Sequences peptidiques et d'acides nucleiques de mini-dystrophine |
| NZ618298A (en) | 2001-11-13 | 2015-04-24 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| PT2359869T (pt) | 2001-12-17 | 2019-04-16 | Univ Pennsylvania | Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas |
| EP2292780B1 (fr) | 2003-09-30 | 2017-08-23 | The Trustees Of The University Of Pennsylvania | Variantes des virus associés aux adenovirus (AAV), séquences, vecteurs les contenant, et leur utilisation |
| EP2960336A1 (fr) | 2014-06-27 | 2015-12-30 | Genethon | Traitement systémique efficace de pathologies dystrophiques musculaires |
-
2014
- 2014-06-27 EP EP14174848.3A patent/EP2960336A1/fr not_active Withdrawn
-
2015
- 2015-04-24 WO PCT/EP2015/058964 patent/WO2015197232A1/fr not_active Ceased
- 2015-04-24 CA CA2953187A patent/CA2953187A1/fr active Pending
- 2015-04-24 US US15/321,416 patent/US10166272B2/en active Active
- 2015-06-29 ES ES15731377.6T patent/ES2679621T3/es active Active
- 2015-06-29 NO NO15731377A patent/NO3044319T3/no unknown
- 2015-06-29 DK DK15731377.6T patent/DK3044319T3/en active
- 2015-06-29 WO PCT/EP2015/064703 patent/WO2015197869A1/fr not_active Ceased
- 2015-06-29 EP EP15731377.6A patent/EP3044319B1/fr active Active
- 2015-06-29 CN CN201580035098.7A patent/CN106659804A/zh active Pending
- 2015-06-29 CN CN202410802637.6A patent/CN118767171A/zh active Pending
- 2015-06-29 TR TR2018/11260T patent/TR201811260T4/tr unknown
- 2015-06-29 JP JP2017519971A patent/JP6656240B2/ja active Active
- 2015-06-29 EP EP18175920.0A patent/EP3395950A1/fr not_active Withdrawn
-
2018
- 2018-11-09 US US16/185,248 patent/US10786546B2/en active Active
-
2020
- 2020-01-31 JP JP2020014974A patent/JP6894062B2/ja active Active
- 2020-08-24 US US17/000,867 patent/US12023366B2/en active Active
-
2021
- 2021-03-24 JP JP2021049979A patent/JP7325468B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN106659804A (zh) | 2017-05-10 |
| US20200405810A1 (en) | 2020-12-31 |
| JP2021105010A (ja) | 2021-07-26 |
| WO2015197869A1 (fr) | 2015-12-30 |
| CN118767171A (zh) | 2024-10-15 |
| JP6894062B2 (ja) | 2021-06-23 |
| US20170157213A1 (en) | 2017-06-08 |
| JP2017521492A (ja) | 2017-08-03 |
| EP3395950A1 (fr) | 2018-10-31 |
| JP2020079268A (ja) | 2020-05-28 |
| CA2953187A1 (fr) | 2015-12-30 |
| JP7325468B2 (ja) | 2023-08-14 |
| US10786546B2 (en) | 2020-09-29 |
| JP6656240B2 (ja) | 2020-03-04 |
| EP3044319B1 (fr) | 2018-06-06 |
| US12023366B2 (en) | 2024-07-02 |
| DK3044319T3 (en) | 2018-07-30 |
| US20190167762A1 (en) | 2019-06-06 |
| ES2679621T3 (es) | 2018-08-29 |
| US10166272B2 (en) | 2019-01-01 |
| EP2960336A1 (fr) | 2015-12-30 |
| TR201811260T4 (tr) | 2018-09-21 |
| EP3044319A1 (fr) | 2016-07-20 |
| WO2015197232A1 (fr) | 2015-12-30 |